Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Performance of Treponemal Tests for the Diagnosis of Syphilis.

Park IU, Fakile YF, Chow JM, Gustafson KJ, Jost H, Schapiro JM, Novak-Weekley S, Tran A, Nomura JH, Chen V, Beheshti M, Tsai T, Hoover K, Bolan G.

Clin Infect Dis. 2019 Mar 5;68(6):913-918. doi: 10.1093/cid/ciy558.

PMID:
29986091
2.

Correlation of Treponemal Immunoassay Signal Strength Values with Reactivity of Confirmatory Treponemal Testing.

Fakile YF, Jost H, Hoover KW, Gustafson KJ, Novak-Weekley SM, Schapiro JM, Tran A, Chow JM, Park IU.

J Clin Microbiol. 2017 Dec 26;56(1). pii: e01165-17. doi: 10.1128/JCM.01165-17. Print 2018 Jan.

3.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.

Paredes R, Tzou PL, van Zyl G, Barrow G, Camacho R, Carmona S, Grant PM, Gupta RK, Hamers RL, Harrigan PR, Jordan MR, Kantor R, Katzenstein DA, Kuritzkes DR, Maldarelli F, Otelea D, Wallis CL, Schapiro JM, Shafer RW.

PLoS One. 2017 Jul 28;12(7):e0181357. doi: 10.1371/journal.pone.0181357. eCollection 2017.

4.

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.

Rhee SY, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, Cooper DA, Nsanzimana S, Saravanan S, Charpentier C, de Oliveira T, Etiebet MA, Garcia F, Goedhals D, Gomes P, Günthard HF, Hamers RL, Hoffmann CJ, Hunt G, Jiamsakul A, Kaleebu P, Kanki P, Kantor R, Kerschberger B, Marconi VC, D'amour Ndahimana J, Ndembi N, Ngo-Giang-Huong N, Rokx C, Santoro MM, Schapiro JM, Schmidt D, Seu L, Sigaloff KCE, Sirivichayakul S, Skhosana L, Sunpath H, Tang M, Yang C, Carmona S, Gupta RK, Shafer RW.

EBioMedicine. 2017 Apr;18:225-235. doi: 10.1016/j.ebiom.2017.03.024. Epub 2017 Mar 19.

5.

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection.

Seden K, Gibbons S, Marzolini C, Schapiro JM, Burger DM, Back DJ, Khoo SH.

PLoS One. 2017 Mar 23;12(3):e0173509. doi: 10.1371/journal.pone.0173509. eCollection 2017.

6.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, De Oliveira T, Wensing AM, Gallant JE, Wainberg MA, Richman DD, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, Shafer RW.

PLoS One. 2015 Dec 30;10(12):e0145772. doi: 10.1371/journal.pone.0145772. eCollection 2015.

7.

Discordant Syphilis Immunoassays in Pregnancy: Perinatal Outcomes and Implications for Clinical Management.

Mmeje O, Chow JM, Davidson L, Shieh J, Schapiro JM, Park IU.

Clin Infect Dis. 2015 Oct 1;61(7):1049-53. doi: 10.1093/cid/civ445. Epub 2015 Jun 10.

8.

Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.

Lamorde M, Schapiro JM, Burger D, Back DJ.

AIDS. 2014 Nov 13;28(17):2551-63. doi: 10.1097/QAD.0000000000000439. Review.

PMID:
25574958
9.
10.

Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes.

Grossman Z, Schapiro JM, Levy I, Elbirt D, Chowers M, Riesenberg K, Olstein-Pops K, Shahar E, Istomin V, Asher I, Gottessman BS, Shemer Y, Elinav H, Hassoun G, Rosenberg S, Averbuch D, Machleb-Guri K, Kra-Oz Z, Radian-Sade S, Rudich H, Ram D, Maayan S, Agmon-Levin N, Sthoeger Z.

PLoS One. 2014 Jan 27;9(1):e86239. doi: 10.1371/journal.pone.0086239. eCollection 2014.

11.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

12.

Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.

De Luca A, Hamers RL, Schapiro JM.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S63-9. doi: 10.1093/infdis/jit109. Review.

PMID:
23687291
13.

Genetic polymorphism of IL28B in hepatitis C-infected haemophilia patients in Israel.

Maor Y, Morali G, Bashari D, Pénaranda G, Schapiro JM, Martinowitz U, Halfon P.

Haemophilia. 2013 Jan;19(1):150-6. doi: 10.1111/j.1365-2516.2012.02932.x. Epub 2012 Aug 23.

PMID:
22913807
14.

Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.

Santos JR, Llibre JM, Imaz A, Domingo P, Iribarren JA, Mariño A, Miralles C, Galindo MJ, Ornelas A, Moreno S, Schapiro JM, Clotet B; Call Conference Group.

J Antimicrob Chemother. 2012 Jun;67(6):1462-9. doi: 10.1093/jac/dks080. Epub 2012 Mar 19.

PMID:
22431669
15.

Screening for syphilis with the treponemal immunoassay: analysis of discordant serology results and implications for clinical management.

Park IU, Chow JM, Bolan G, Stanley M, Shieh J, Schapiro JM.

J Infect Dis. 2011 Nov;204(9):1297-304. doi: 10.1093/infdis/jir524. Epub 2011 Sep 19.

PMID:
21930610
16.

Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.

Schapiro JM, Boucher CA, Kuritzkes DR, van de Vijver DA, Llibre JM, Lewis M, Simpson P, Delogne C, McFadyen L, Chapman D, Perros M, Valdez H, van der Ryst E, Westby M.

Antivir Ther. 2011;16(3):395-404. doi: 10.3851/IMP1759.

PMID:
21555822
17.

An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature.

Bruno CB, Schapiro JM, Saberi P.

J Int Assoc Physicians AIDS Care (Chic). 2011 Jul-Aug;10(4):219-22. doi: 10.1177/1545109711404945. Epub 2011 Apr 25. Review.

18.

European guidelines on the clinical management of HIV-1 tropism testing.

Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CA; European Consensus Group on clinical management of tropism testing.

Lancet Infect Dis. 2011 May;11(5):394-407. doi: 10.1016/S1473-3099(10)70319-4. Epub 2011 Mar 21. Review.

PMID:
21429803
19.

Update of the drug resistance mutations in HIV-1: December 2010.

Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2010 Dec;18(5):156-63. Review.

20.

Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score.

Schapiro JM, Scherer J, Boucher CA, Baxter JD, Tilke C, Perno CF, Maggiolo F, Santoro MM, Hall DB.

Antivir Ther. 2010;15(7):1011-9. doi: 10.3851/IMP1670.

PMID:
21041916
21.

Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.

Zolfo M, Schapiro JM, Phan V, Koole O, Thai S, Vekemans M, Fransen K, Lynen L.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):727-35. doi: 10.1089/AID.2010.0037. Epub 2010 Nov 23.

PMID:
20854169
22.

Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis.

Chowers M, Gottesman BS, Leibovici L, Schapiro JM, Paul M.

Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):779-86. doi: 10.1007/s10096-010-0926-y. Epub 2010 May 7. Review.

PMID:
20449621
23.

Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.

Llibre JM, Schapiro JM, Clotet B.

Clin Infect Dis. 2010 Mar 15;50(6):872-81. doi: 10.1086/650732. Review.

PMID:
20158400
24.

Update of the drug resistance mutations in HIV-1: December 2009.

Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2009 Dec;17(5):138-45. Review. No abstract available.

25.

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW.

PLoS One. 2009;4(3):e4724. doi: 10.1371/journal.pone.0004724. Epub 2009 Mar 6.

26.

Update of the Drug Resistance Mutations in HIV-1.

Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2008 Dec;16(5):138-45. Review. Erratum in: Top HIV Med. 2009 Feb-Mar;17(1):13.

27.

A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study.

Clotet B, Capetti A, Soto-Ramirez LE, Gatell JM, Rowell L, Salgo M, Schapiro JM.

J Antimicrob Chemother. 2008 Dec;62(6):1374-8. doi: 10.1093/jac/dkn377. Epub 2008 Sep 8.

PMID:
18782780
28.

Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.

Elliott JH, Lynen L, Calmy A, De Luca A, Shafer RW, Zolfo M, Clotet B, Huffam S, Boucher CA, Cooper DA, Schapiro JM.

AIDS. 2008 Oct 18;22(16):2053-67. doi: 10.1097/QAD.0b013e328309520d. Review. No abstract available.

PMID:
18753937
29.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD; International AIDS Society-USA.

Top HIV Med. 2008 Aug-Sep;16(3):266-85.

PMID:
19856548
30.

HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Shafer RW, Schapiro JM.

AIDS Rev. 2008 Apr-Jun;10(2):67-84. Review.

31.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD.

Clin Infect Dis. 2008 Jul 15;47(2):266-85. doi: 10.1086/589297.

32.

Update of the drug resistance mutations in HIV-1: Spring 2008.

Johnson VA, Brun-Vezinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2008 Apr-May;16(1):62-8. No abstract available. Erratum in: Top HIV Med. 2008 Oct-Nov;16(4):121.

33.

Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience.

Maor Y, Schapiro JM, Bashari D, Lurie Y, Safadi R, Segol O, Paritsky M, Rachlis Z, Avidan B, Bar-Meir S, Martinowitz U.

Haemophilia. 2008 Mar;14(2):336-42. doi: 10.1111/j.1365-2516.2007.01633.x. Epub 2008 Jan 16.

PMID:
18205802
34.

Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.

Llibre JM, Domingo P, del Pozo MA, Miralles C, Galindo MJ, Viciana I, Moreno S, Schapiro JM, Clotet B.

J Antimicrob Chemother. 2008 Jan;61(1):206-9. Epub 2007 Nov 13.

PMID:
17999972
35.

Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.

Maor Y, Calès P, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Pénaranda G, Bar-Meir S, Martinowitz U, Halfon P.

Haemophilia. 2007 Nov;13(6):722-9.

PMID:
17973848
36.

Update of the drug resistance mutations in HIV-1: 2007.

Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2007 Aug-Sep;15(4):119-25. Review. No abstract available.

37.

In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.

Dandache S, Sévigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ.

Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16.

38.

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D.

AIDS. 2007 Jan 11;21(2):215-23. Review.

39.

Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.

Averbuch D, Schapiro JM, Lanier ER, Gradstein S, Gottesman G, Kedem E, Einhorn M, Grisaru-Soen G, Ofir M, Engelhard D, Grossman Z.

Pediatr Infect Dis J. 2006 Nov;25(11):1049-56.

PMID:
17072129
40.

Update of the drug resistance mutations in HIV-1: Fall 2006.

Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2006 Aug-Sep;14(3):125-30.

41.

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.

Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, Mayers DL.

J Virol. 2006 Nov;80(21):10794-801. Epub 2006 Aug 23.

42.

Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?

Maor Y, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Pénaranda G, Bar-Meir S, Martinowitz U, Halfon P.

Haemophilia. 2006 Jul;12(4):372-9.

PMID:
16834736
43.

HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes.

Rhee SY, Kantor R, Katzenstein DA, Camacho R, Morris L, Sirivichayakul S, Jorgensen L, Brigido LF, Schapiro JM, Shafer RW; International Non Subtype B HIV-1 Working Group.

AIDS. 2006 Mar 21;20(5):643-51.

44.

Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent.

Snoeck J, Kantor R, Shafer RW, Van Laethem K, Deforche K, Carvalho AP, Wynhoven B, Soares MA, Cane P, Clarke J, Pillay C, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-Vézinet F, Reid C, Cahn P, Brigido LF, Grossman Z, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan RP, Camacho R, Schapiro JM, Katzenstein D, Vandamme AM.

Antimicrob Agents Chemother. 2006 Feb;50(2):694-701.

45.

Hepatitis C at the israeli national hemophilia center.

Maor Y, Bashari D, Kenet G, Lalezari S, Lubetsky A, Luboshitz J, Schapiro JM, Avidan B, Bar-Meir S, Martinowitz U.

Haemophilia. 2006 Jan;12(1):68-74.

PMID:
16409178
46.

Update of the drug resistance mutations in HIV-1: Fall 2005.

Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD.

Top HIV Med. 2005 Oct-Nov;13(4):125-31.

47.

HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.

Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, Horberg M, Flamm J, Follansbee S, Schapiro JM, Shafer RW.

J Infect Dis. 2005 Aug 1;192(3):456-65. Epub 2005 Jul 5.

48.

Drug resistance and antiretroviral drug development.

Shafer RW, Schapiro JM.

J Antimicrob Chemother. 2005 Jun;55(6):817-20. Epub 2005 Apr 21. Review.

49.

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW.

PLoS Med. 2005 Apr;2(4):e112. Epub 2005 Apr 26.

50.

Drug-resistant HIV infection among drug-naive patients in Israel.

Grossman Z, Lorber M, Maayan S, Bar-Yacov N, Levy I, Averbuch D, Istomin V, Chowers M, Sthoeger Z, Ram D, Rudich H, Mileguir F, Pavel R, Almaliach R, Schlaeffer F, Kra-Oz Z, Mendelson E, Schapiro JM, Riesenberg K.

Clin Infect Dis. 2005 Jan 15;40(2):294-302. Epub 2004 Dec 20.

PMID:
15655750

Supplemental Content

Loading ...
Support Center